Project Grant R01HL174012
Award Date
7/15/25
Completion Date
4/30/29
Dollars Obligated
$784K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,564,220 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, on Sep 17, 2024. The grant funds the development of an imaging-compatible pre-clinical ex vivo lung perfusion (EVLP) system to obtain structural, functional, and metabolic biomarkers of donor lung health. The project aims to use these...
This $715,110 Project Grant, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on February 1, 2025, supports the preclinical evaluation of a novel peptide-amphiphile derived toroidal oxygen carrier. The goal is to design and optimize a "blood substitute prototype" based on a deformable nanoparticle that encapsulates hemoglobin and incorporates mechanisms to control oxygen binding and release. Key aspects include computational...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
The federal Project Grant award R01HL177087 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $605,678 award supports research to explore a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. Specifically, the research aims to investigate how reactive oxygen species generated during hypoxia induce oxidative modifications in DNA regulatory sequences, which recruit enzymes that...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,916 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The 5-year grant, which runs from August 2024 to June 2029, aims to create and validate a tool to calculate the contribution of each phenotype of bronchopulmonary dysplasia (BPD) to elevated breathing effort, known as the work of breathing (WOB), in premature neonates. The research...
The National Heart Lung and Blood Institute (NHLBI) awarded a $1,547,467 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Ohio State University to conduct research on the genetic regulation of inflammation resolution following myocardial infarction. The 5-year project aims to elucidate the impact of genetic variations in T regulatory cell CD39 expression on cardiac inflammation and healing after a heart attack. The research will leverage murine models and human patient...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This federal Project Grant award of $583,233, provided by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research, supports research aimed at developing novel strategies to prevent or treat secondary organ complications in multi-organ failure. The key objectives of the funded research are to: 1) identify the domains of the protein osteopontin (OPN) and its receptor CD44 that are required to induce remote lung inflammation following acute...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...
This $2,803,961 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a collaborative research effort to investigate the mechanisms underlying primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) in lung transplant recipients. The research team at Northwestern University will conduct four interrelated projects to better understand the role of lung-restricted alloantibodies,...